Edmonton protocol

From WikiMD's Medical Encyclopedia

Revision as of 17:20, 18 March 2025 by Prab (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Edmonton Protocol is a medical procedure that involves the transplantation of islet cells into a patient suffering from Type 1 diabetes. This procedure was developed at the University of Alberta, in Edmonton, Canada, hence the name.

History[edit]

The Edmonton Protocol was first developed and implemented in 1999 by a team of researchers led by Dr. James Shapiro. The team's groundbreaking work was published in the New England Journal of Medicine and has since been recognized as a significant advancement in the treatment of Type 1 diabetes.

Procedure[edit]

The Edmonton Protocol involves the transplantation of islet cells from a donor pancreas into the liver of a patient with Type 1 diabetes. The islet cells are infused into the patient's portal vein, where they lodge in the liver and begin to produce insulin.

Eligibility[edit]

Not all patients with Type 1 diabetes are eligible for the Edmonton Protocol. Candidates must have severe hypoglycemia unawareness and must have experienced at least one life-threatening hypoglycemic episode. They must also have poor blood glucose control despite optimal medical management.

Outcomes[edit]

While the Edmonton Protocol has shown promise, it is not a cure for Type 1 diabetes. Most patients still require some insulin therapy after the procedure. However, many patients experience a significant reduction in their insulin requirements and an improvement in their blood glucose control.

Limitations and Risks[edit]

The Edmonton Protocol is not without its limitations and risks. These include the limited availability of donor pancreases, the need for lifelong immunosuppressive therapy to prevent rejection of the transplanted islet cells, and the potential for complications related to the procedure itself.

Future Research[edit]

Research is ongoing to improve the outcomes of the Edmonton Protocol and to overcome its limitations. This includes research into alternative sources of islet cells, such as stem cells, and methods to reduce the need for immunosuppressive therapy.

This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.